NDAORALFOR SUSPENSION
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LORABID (loracarbef) is an oral carbacephem antibiotic approved by Pfizer in 1991 for bacterial infections. It is formulated as a suspension for oral administration and is used to treat susceptible infections in both pediatric and adult populations. The drug functions as a beta-lactam antibiotic with a mechanism similar to cephalosporins.
LOE Approaching
With LOE approaching and moderate competitive pressure, the brand team is likely in maintenance or transition mode with limited growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LORABID offers limited career growth due to its LOE-approaching status and zero linked job openings. Roles on this product are primarily focused on maximizing remaining revenue and managing the transition to generic competition rather than driving innovation or expansion.
Brand ManagerField Sales Representative
Worked on LORABID at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.